Format

Send to:

Choose Destination
See comment in PubMed Commons below
Health Econ Rev. 2013 May 7;3:13. doi: 10.1186/2191-1991-3-13. eCollection 2013.

Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain.

Author information

  • 1Medical & HEOR Department, TEVA Pharmaceutical, Calle Anabel Segura, 11-1ª planta, Alcobendas, Madrid, 28108, Spain.
  • 2Pharmacoeconomics and Outcomes Research Iberia Edificio CEP Altagracia I Calle Segundo Mata, 1 (2ª Planta), Pozuelo de Alarcón, Madrid, 28224, Spain.

Abstract

BACKGROUND:

Fingolimod is an innovative drug with a significant budget impact in the treatment of MS in Spain. The aim of this study was to calculate the direct cost comparison of glatiramer acetate and fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in Spain.

METHODS:

A cost analysis model was developed to compare glatiramer acetate and fingolimod, based on a 1-year time horizon. In addition to the pharmacological costs, resource use was estimated for glatiramer acetate (1 hour of training with nursing staff in self-injection techniques for subcutaneous administration) and fingolimod (vaccination for varicella-zoster virus in 5% of patients, 3 complete blood counts per year, 3 ophthalmology visits for prevention of macular edema, 3 transaminase tests to monitor liver function, and cardiovascular monitoring consisting of 1 ECG before the first fingolimod dose and at 6 hours; 1 day outpatients-hospital visit for cardiological monitoring during 6 hours on the day of the first fingolimod dose, with follow-up of blood pressure and heart rate every hour). The pharmacological costs were calculated based on the ex-factory price of the drugs evaluated, using the doses recommended in the respective Summary of Products Characteristics (SmPC). Total invoicing volume was discounted by 7.5%, as laid down in Spanish Royal Decree 8/2010. Unit costs were obtained from the e-Salud database and the drug catalog. Costs in the model are expressed in €2012.

RESULTS:

The cost of annual treatment was €9,439.42 for glatiramer acetate and €19,602.18 for fingolimod, yielding a cost difference of €10,162.76. Assuming a fixed budget of €100,000.00, approximately 10 patients could be treated with glatiramer acetate, compared to 5 with fingolimod.

CONCLUSIONS:

Fingolimod therapy requires twice the investment as glatiramer acetate.

KEYWORDS:

Cost analysis model; Economic evaluation; Fingolimod; Glatiramer acetate; Relapsing-remitting multiple sclerosis (RRMS)

PMID:
23647721
[PubMed]
PMCID:
PMC3651713
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk